.svg)
.png)
What's the Problem?
Cell therapies are revolutionizing healthcare. One of such therapies are CAR-T cells, and they have saved thousands of lives by leveraging the power of human T cells to fight diseases like cancer. However, 1) these therapies are highly exclusive, in the order of USD 450K per patient plus patient hospitalization care costs; and 2) in some cases, such as solid tumors, the therapeutic failure rate exceeds 50%. It is a consensus in the community that a key driver of therapeutic failure is related to the decreasing quality of T cells (they become older and less functional) during the manufacturing process of these therapies. In addition, there is poor persistence and loss of functional attributes of these cells upon reinfusion into the patient, thus limiting long-term therapeutic response.
How are they Solving it?
We have developed an innovative approach to enhance CAR-T cell functionality by reprogramming cells to rejuvenate and improve their performance and response durability. Our targeted discovery process uses transcriptomic analyses and bioinformatics to identify key molecular targets, followed by in vitro and in vivo evaluation of candidate molecules that induce desired effects in the cells. This has led to the identification of molecules that not only promote the increase in cell functionality but also induce cell rejuvenation. In addition, to evaluate the effectiveness of cell reprogramming, we have optimized a post-reprogramming screening platform by analyzing a set of important cellular biomarkers. By integrating this cell reprogramming technology into the CAR-T manufacturing workflow, more powerful and effective cancer therapies will be delivered to patients in need.
Next Startup
Invitrall
.svg)
Sign up for our newsletter
Designed by Palta Tech
Designed by Palta 🥑
Teodoro García 2474,
Buenos Aires, Argentina
